文献速递类风湿关节炎

利用PPARα激动优化糖皮质激素治疗类风湿关节炎的疗效安全性比

Optimizing Efficacy to Safety Ratio of Glucocorticoids in Rheumatoid Arthritis Models by Leveraging Peroxisome Proliferator-Activated Nuclear Receptor-α Agonism.
PubMed 文献 · Arthritis Rheumatol · 2026-09-07

该研究在TNFα刺激的L929sA成纤维细胞、骨关节炎(OA)与类风湿关节炎(RA)患者原代成纤维样滑膜细胞(FLS)及胶原诱导性关节炎小鼠中,评估地塞米松与PPARα激动剂GW7647联用的效果。结果显示GW7647可增强地塞米松的抗炎作用,并在体内抵消地塞米松诱导的肥胖和高甘油三酯血症而不影响关节炎严重程度,且在RA-FLS和OA-FLS中协同调控代谢基因表达。

要点

  • GW7647增强地塞米松对TNFα炎症反应的抑制。
  • GW7647抵消地塞米松体内诱导的肥胖和高甘油三酯血症。
  • 联用不损害地塞米松控制关节炎的疗效。

核心结论

  • PPARα激动可增强糖皮质激素在L929sA细胞中的抗炎效果,并在体内减轻地塞米松的代谢副作用而不损害其疗效。

研究设计与样本

  • 研究在四种模型系统中评估地塞米松与PPARα激动剂GW7647:TNFα刺激的L929sA成纤维细胞、OA与RA患者原代FLS、胶原诱导性关节炎小鼠。

主要发现

  • 地塞米松降低L929sA细胞对TNFα的炎症反应,GW7647进一步增强该作用。
  • 体内地塞米松诱导肥胖和高甘油三酯血症,GW7647可抵消这些代谢效应而不影响关节炎严重程度。
  • 在OA-FLS和RA-FLS中,地塞米松与GW7647协同调控代谢基因表达。
  • TNFα刺激的人OA-FLS蛋白组学显示,地塞米松与GW7647联用抑制干扰素刺激蛋白。
  • 在TNFα与干扰素-β共刺激的L929sA中,联用对促炎基因表达的抑制比单用TNFα更明显。

临床怎么用

  • 糖皮质激素与PPAR激动剂均已广泛用于临床,二者联用可能成为优化糖皮质激素治疗的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glucocorticoids remain essential therapies for immune and inflammatory diseases such as rheumatoid arthritis (RA) but are notorious for their metabolic side effects. Given the anti-inflammatory and metabolically favorable actions of peroxisome proliferator-activated nuclear receptor (PPAR) agonists, we investigated whether PPARα agonism could enhance the therapeutic efficacy and/or mitigate the metabolic side effects of glucocorticoids. METHODS: We evaluated the effects of the synthetic glucocorticoid dexamethasone and the PPARα agonist GW7647 across four model systems: tumor necrosis factor-α (TNFα)-stimulated L929sA fibroblasts, primary human fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and RA, and collagen-induced arthritis mice. RESULTS: Dexamethasone reduced the inflammatory TNFα response in L929sA cells, which was further potentiated by GW7647. In vivo, dexamethasone induced adiposity and hypertriglyceridemia, which GW7647 counteracted without affecting arthritis severity. In both OA-FLS and RA-FLS, dexamethasone and GW7647 cooperatively regulated metabolic genes expression. Proteomic profiling of TNFα-stimulated human OA-FLS revealed that combined use of dexamethasone and GW suppressed interferon-stimulated proteins. In line herewith, suppression of proinflammatory gene expression upon combined dexamethasone and GW7647 treatment was more outspoken in L929sA co-stimulated with TNFα and interferon-β compared to TNFα alone. CONCLUSION: GW enhances the anti-inflammatory effects of glucocorticoids in L929sA cells and mitigates metabolic side effects of dexamethasone in vivo, without compromising efficacy. In human OA-FLS and RA-FLS, this combination cooperatively regulates metabolic gene expression. Moreover, PPARα agonism permits to broaden its anti-inflammatory profile to interferon-driven pathways. Because both glucocorticoids and PPAR agonists are already widely used in clinical practice, these findings offer a promising strategy to optimize glucocorticoid-based therapies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Koorneef LL, Gilis E, Clarisse D, et al. Optimizing Efficacy to Safety Ratio of Glucocorticoids in Rheumatoid Arthritis Models by Leveraging Peroxisome Proliferator-Activated Nuclear Receptor-α Agonism. Arthritis Rheumatol. 2026. PMID: 42703802. doi:10.1002/art.70331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。